Paul M. Van Den Berk
Leiden, ZH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Model-Informed Drug Development for Daprodustat Supports the Design of Individualized Dosing Regimens in Chronic Kidney Disease Patients With Anemia.
Journal: Clinical pharmacology and therapeutics
Published: March 13, 2025
Integrated Longitudinal Population Dose-Hemoglobin Response of Daprodustat Following Dose Titration in Patients With Anemia in Chronic Kidney Disease.
Journal: Clinical pharmacology and therapeutics
Published: June 19, 2024
Molecular dependencies and genomic consequences of a global DNA damage tolerance defect.
Journal: Genome biology
Published: February 22, 2024
Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKD.
Journal: Diabetes, obesity & metabolism
Published: September 06, 2023
Dual role of proliferating cell nuclear antigen monoubiquitination in facilitating Fanconi anemia-mediated interstrand crosslink repair.
Journal: PNAS nexus
Published: July 19, 2023
A C57BL/6J Fancg-KO Mouse Model Generated by CRISPR/Cas9 Partially Captures the Human Phenotype.
Journal: International journal of molecular sciences
Published: June 14, 2023
Mammalian life depends on two distinct pathways of DNA damage tolerance.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: January 20, 2023
Huwe1 supports B-cell development, B-cell-dependent immunity, somatic hypermutation and class switch recombination by regulating proliferation.
Journal: Frontiers in immunology
Published: July 05, 2022
Division of labor within the DNA damage tolerance system reveals non-epistatic and clinically actionable targets for precision cancer medicine.
Journal: Nucleic acids research
Published: April 12, 2022
Green tooth discoloration in a two-year-old boy
Journal: Nederlands tijdschrift voor tandheelkunde
Published: November 08, 2021
Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis.
Journal: Clinical pharmacokinetics
Published: October 08, 2021
Last Updated: 09/26/2026